

Spark NIR™ 685 anti-human HLA-A,B,C

Catalog # / 2157265 / 25 tests
Size: 2157270 / 100 tests

Clone: W6/32


Isotype: Mouse IgG2a, κ

Reactivity: Human, Non-human primate, Other

Preparation: The antibody was purified by affinity chromatography and conjugated with Spark NIR™ 685 under optimal conditions.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA)

Concentration: Lot-specific



Human peripheral blood lymphocytes were stained with HLA-A,B,C (clone W6/32) Spark NIR™ 685 (filled histogram) or mouse IgG2a, κ Spark NIR™ 685 isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

* Spark NIR™ 685 has a maximum excitation of 665 nm and a maximum emission of 685 nm.

Application Notes: Clone W6/32 recognizes residues in the N terminus of the human β2-microglobulin molecule²¹.

Additional reported applications (for the relevant formats) include: immunoprecipitation², Western blotting (non-reducing)³, immunohistochemical staining of acetone-fixed frozen tissue sections^{4,5}, blocking^{6,7}, inhibition of NK cell-mediated lysis¹⁰, and activation^{8,9}. Clone W6/32 has been reported not to be suitable for immunohistochemistry on paraffin sections¹⁷. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays. For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 311428) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

**Application
References:**

1. Darrow TL, et al. 1989. *J. Immunol.* 142:3329.
2. Stern P, et al. 1987. *J. Immunol.* 138:1088.
3. Tran TM, et al. 2001. *Immunogenetics* 53:440.
4. Barbatis C, et al. 1981. *Gut* 22:985.
5. Ayyoub M, et al. 2004. *Cancer Immunity* 4:7.
6. DeFelice M, et al. 1990. *Cell. Immunol.* 126:420.
7. Fayen J, et al. 1998. *Int. Immunol.* 10:1347.
8. Turco MC, et al. 1988. *J. Immunol.* 141:2275.
9. Geppert TD, et al. 1989. *J. Immunol.* 142:3763.
10. Wooden SL, et al. 2005. *J. Immunol.* 175:1383.
11. Nagano M, et al. 2007. *Blood* 110:151.
12. McLoughlin RM, et al. 2008. *J. Immunol.* 181:1323. [PubMed](#)
13. Takahara M, et al. 2008. *J. Leukoc. Biol.* 83:742. [PubMed](#)
14. Lunemann A, et al. 2008. *J. Immunol.* 181:6170. [PubMed](#)
15. Laing BJ, et al. 2010. *J. Thorac Cardiovasc Surg.* 139:1402. [PubMed](#)
16. Yoshino N, et al. 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
17. Vambutas A, et al. 2000. *Clin. Diagn. Lab. Immun.* 7:79.
18. Coppieters KT, et al. 2012. *J. Exp. Med.* 209:51. (epitope)
19. Crivello P, et al. 2013. *Hum Immunol.* 22:100. [PubMed](#)
20. Jung Y, et al. 2015. *Mol Cancer Res.* 13:197. [PubMed](#)
21. Shields MJ, Ribaldo RK. 1998. *Tissue Antigens.* 51(5):567-70. (epitope)

Description: MHC class I antigens associated with β 2-microglobulin are expressed by all human nucleated cells. MHC class I molecules are involved in presentation of antigens to CD8⁺ T cells. They play an important role in cell-mediated immune responses and tumor surveillance.

**Antigen
References:** 1. Barclay AN, et al. Eds. 1993. *The Leukocyte Antigen FactsBook*. Academic Press Inc. San Diego.